Skip to Content

Tecfidera (dimethyl fumarate) Disease Interactions

There are 4 disease interactions with Tecfidera (dimethyl fumarate):


Immunosuppressive Agents (Includes Tecfidera) ↔ Infections

Severe Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.


Immunosuppressive Agents (Includes Tecfidera) ↔ Pml

Severe Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.


Dimethyl Fumarate (Includes Tecfidera) ↔ Liver

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The use of dimethyl fumarate may cause liver injury. Elevations of hepatic transaminases were observed during controlled trials. It is recommended to obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels prior to treatment and during treatment, as clinically indicated. Caution is recommended when prescribing this agent in patients at risk for liver injury. Discontinue therapy if clinically significant liver injury induced by this agent is suspected.


Dimethyl Fumarate (Includes Tecfidera) ↔ Lymphopenia

Moderate Potential Hazard, Moderate plausibility

Applies to: Lymphocytopenia

The use of dimethyl fumarate may decrease lymphocyte counts. It is recommended to obtain a CBC count before initiating treatment, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interrupting therapy in patients with lymphocyte counts less than 0.5 x 109/L persisting for more than six months and withhold treatment from patients with serious infections until resolution. Caution is recommended and the decisions about whether or not to restart therapy in these patients should be individualized based on clinical circumstances.

Tecfidera (dimethyl fumarate) drug Interactions

There are 94 drug interactions with Tecfidera (dimethyl fumarate)

Tecfidera (dimethyl fumarate) alcohol/food Interactions

There is 1 alcohol/food interaction with Tecfidera (dimethyl fumarate)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.